AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nature Reviews Neurology

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrneurol.2010.72PMID 20639914
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells.

  2010cited by this paper
• Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica Patients

  2010cited by this paper
• Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

  2010cited by this paper
• Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome.

  2010cited by this paper
• Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen.

  2010cited by this paper
• Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders

  2010cited by this paper
• B-CELL ACTIVATING FACTOR OF THE TNF FAMILY IS UPREGULATED IN NEUROMYELITIS OPTICA

  2010cited by this paper
• NMO-IgG DETECTED IN CSF IN SERONEGATIVE NEUROMYELITIS OPTICA

  2009cited by this paper
• Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

  2009cited by this paper
• Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum

  2009cited by this paper
• Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica.

  2009cited by this paper
• Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody

  2009cited by this paper
• Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution

  2009cited by this paper
• Crystal structure of human aquaporin 4 at 1.8 Å and its mechanism of conductance

  2009cited by this paper
• Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica.

  2009cited by this paper
• Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG.

  2009cited by this paper
• POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN NEUROMYELITIS OPTICA SPECTRUM DISORDERS

  2009cited by this paper
• Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica.

  2009cited by this paper
• AQP4-IgG immunoprecipitation assay optimization.

  2009cited by this paper
• A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset

  2009cited by this paper
• Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions

  2009cited by this paper
• Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo

  2009cited by this paper
• Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica

  2009cited by this paper
• Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis

  2009cited by this paper
• Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese

  2009cited by this paper
• Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis

  2009cited by this paper
• PROCALCITONIN MIGHT HELP IN DISCRIMINATION BETWEEN MENINGEAL NEURO-BEHçET DISEASE AND BACTERIAL MENINGITIS

  2009cited by this paper
• Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker

  2009cited by this paper
• Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study.

  2009cited by this paper
• Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection.

  2009cited by this paper
• Live Cell Analysis of Aquaporin-4 M1/M23 Interactions and Regulated Orthogonal Array Assembly in Glial Cells*♦

  2009cited by this paper
• Aquaporin‐4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies

  2009cited by this paper
• POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN NEUROMYELITIS OPTICA SPECTRUM DISORDERS. Authors' reply

  2009cited by this paper
• Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder

  2009cited by this paper
• Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders

  2009cited by this paper
• Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis

  2009cited by this paper
• Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.

  2009cited by this paper
• Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations

  2008cited by this paper
• Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica

  2008cited by this paper
• Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2

  2008cited by this paper
• Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay.

  2008cited by this paper
• Altered blood–brain barrier integrity in adult aquaporin-4 knockout mice

  2008cited by this paper
• Neuromyelitis optica and non organ-specific autoimmunity.

  2008cited by this paper
• NMO-IgG and Devic's neuromyelitis optica: a French experience

  2008cited by this paper
• Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica.

  2008cited by this paper
• Aquaporin-4 autoantibodies in a paraneoplastic context.

  2008cited by this paper
• Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment1

  2008cited by this paper
• CNS aquaporin-4 autoimmunity in children

  2008cited by this paper
• Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

  2008cited by this paper
• Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.

  2008cited by this paper
• Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica.

  2008cited by this paper
• NMO-IgG predicts the outcome of recurrent optic neuritis

  2008cited by this paper
• Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

  2008cited by this paper
• Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes.

  2007cited by this paper
• Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

  2007cited by this paper
• Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica

  2007cited by this paper
• NMO-IgG in the diagnosis of neuromyelitis optica

  2007cited by this paper
• Revised diagnostic criteria for neuromyelitis optica (NMO)

  2007cited by this paper
• Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

  2007cited by this paper
• Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

  2007cited by this paper
• Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.

  2007cited by this paper
• Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter

  2007cited by this paper
• Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica

  2007cited by this paper
• Neuromyelitis optica following CMV primo‐infection

  2007cited by this paper
• Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica

  2007cited by this paper
• Devic’s syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies

  2006cited by this paper
• B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation

  2006cited by this paper
• Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.

  2006cited by this paper
• Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG

  2006cited by this paper
• High CSF neurofilament heavy chain levels in neuromyelitis optica

  2006cited by this paper
• OSMS is NMO, but not MS: proven clinically and pathologically.

  2006cited by this paper
• Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

  2006cited by this paper
• Activation of Kainate Receptors Sensitizes Oligodendrocytes to Complement Attack

  2006cited by this paper
• Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis

  2006cited by this paper
• Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report.

  2006cited by this paper
• Revised diagnostic criteria for neuromyelitis optica

  2006cited by this paper
• An open label study of the effects of rituximab in neuromyelitis optica

  2005cited by this paper
• IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

  2005cited by this paper
• The Journal of Experimental Medicine CORRESPONDENCE

  2005cited by this paper
• The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications

  2005cited by this paper
• A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

  2004cited by this paper
• Activation of humoral immunity and eosinophils in neuromyelitis optica

  2004cited by this paper
• Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica

  2004cited by this paper
• Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgG

  2003cited by this paper
• Aquaporin-4 square array assembly: Opposing actions of M1 and M23 isoforms

  2003cited by this paper
• A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

  2002cited by this paper
• Neuromyelitis Optica

  2002cited by this paper
• Plasma exchange for severe attacks of CNS demyelination: Predictors of response

  2002cited by this paper
• Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.

  2002cited by this paper
• The link between excitotoxic oligodendroglial death and demyelinating diseases

  2001cited by this paper
• The link between excitotoxic oligodendroglial death and demyelinating diseases.

  2001cited by this paper
• The clinical course of neuromyelitis optica (Devic’s syndrome)

  1999cited by this paper
• A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease

  1999cited by this paper
• Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression.

  1996cited by this paper
• Neuromyelitis Optica (Devic's Disease) Following Chicken Pox

  1994cited by this paper
• Neuromyelitis optica (Devic disease) following varicella infection.

  1979cited by this paper

• Rare demyelinating autoimmune diseases and pregnancy outcomes.

  2026cites this paper
• Consistent Detection of Aquaporin-4 Antibodies: A Comparative Analysis Between Fixed and Live Cell-Based Assays.

  2026cites this paper
• Engineering neuroimmune regulation: biomaterial and nanotechnology platforms for neuropathology diagnosis and targeted immunomodulation

  2026cites this paper
• The Mystery of a Negative Workup: A Diagnostic Dilemma in Seronegative Immune-Mediated Transverse Myelitis

  2026cites this paper
• Neuroimmunology and Sleep

  2025cites this paper
• Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses

  2025cites this paper
• Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis

  2025cites this paper
• Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder

  2025cites this paper
• Clinical value of plasma C1q, C3, and C4 in NMOSD and MOGAD.

  2025cites this paper
• Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks.

  2025cites this paper
• Cognitive performances in people with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

  2025cites this paper
• Dual ROCK1/2–MYLK4 Kinase Inhibition Preserves Visual Function in a Rat Model of Neuromyelitis Optica Spectrum Disorder Optic Neuritis

  2025cites this paper
• Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.

  2025cites this paper
• Live Cell-Based Flow Cytometry Assay Versus Commercial Cell-Based Indirect Immunofluorescence Assay of Aquaporin-4 Antibody in Neuromyelitis Optica: A Comparative Study.

  2025cites this paper
• Breaking New Ground: A Seropositive Neuromyelitis Optica (NMOSD) in Ethiopian Patients: A Case Series

  2025cites this paper
• Immune Reactivity to Raw and Processed Foods and Their Possible Contributions to Autoimmunity

  2025cites this paper
• Oligodendroglia in Neuromyelitis Optica Spectrum Disorder.

  2025cites this paper
• Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review.

  2025cites this paper
• Blood‐based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study

  2024cites this paper
• Differentiating multiple sclerosis and neuromyelitis optica spectrum disorders through pontine trigeminal nerve lesions: A comparative MRI study.

  2024cites this paper
• Comparison of ocular changes in multiple sclerosis and neuromyelitis optica spectrum disorder patients

  2024cites this paper
• [The diagnostic effectiveness of criteria for neuromyelitis optica spectrum disorders in the Russian clinical practice].

  2024cites this paper
• Phenotypic and Immunological Characterization of Patients with Activated PI3Kδ Syndrome 1 Presenting with Autoimmunity

  2024cites this paper
• Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends

  2024cites this paper
• Association between FOXP3 polymorphisms and expression and neuromyelitis optica spectrum disorder risk in the Northern Chinese Han population

  2024cites this paper
• A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations

  2024cites this paper
• Exploring resting-state EEG oscillations in patients with Neuromyelitis Optica Spectrum Disorder.

  2024cites this paper
• Abnormal dynamic features of spontaneous brain activity and their concordance in neuromyelitis optica spectrum disorder related optic neuritis: A resting-state fMRI study.

  2024cites this paper
• The Characteristics of Cognitive Proficiency in Patients with Acute Neuromyelitis Optica Spectrum Disease and its Correlation with Serum Aquaporin-4 Antibody Titer

  2023cites this paper
• Myelin Oligodendrocyte Glycoprotein as an Autoantigen in Inflammatory Demyelinating Diseases of the Central Nervous System

  2023cites this paper
• Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs).

  2023cites this paper
• From Homeostasis to Pathology: Decoding the Multifaceted Impact of Aquaporins in the Central Nervous System

  2023cites this paper
• Astrocyte‐Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model

  2023cites this paper
• [Clinical features and modern diagnostic criteria of the disease associated with myelin oligodendrocyte glycoprotein antibody disease].

  2023cites this paper
• Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis

  2023influential citation
• ACT001 Relieves NMOSD Symptoms by Reducing Astrocyte Damage with an Autoimmune Antibody

  2023cites this paper
• Myelin olygodendrocyte glycoprotein - autoantigen in inflammatory demyelinating diseases of the central nervous system

  2023cites this paper
• Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

  2023cites this paper
• The circadian rhythms regulated by Cx43-signaling in the pathogenesis of Neuromyelitis Optica

  2023cites this paper
• Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS.

  2022cites this paper
• Role of the glymphatic system in idiopathic intracranial hypertension.

  2022cites this paper
• Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders

  2022cites this paper
• Cellular Distribution of Brain Aquaporins and Their Contribution to Cerebrospinal Fluid Homeostasis and Hydrocephalus

  2022cites this paper
• Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature

  2022cites this paper
• Genetics behind Cerebral Disease with Ocular Comorbidity: Finding Parallels between the Brain and Eye Molecular Pathology

  2022cites this paper
• A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica.

  2022cites this paper
• Sera of Neuromyelitis Optica Patients Increase BID-Mediated Apoptosis in Astrocytes

  2022cites this paper
• Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD

  2022cites this paper
• IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19.

  2022cites this paper
• Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review

  2022cites this paper
• Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders.

  2022cites this paper
• Relationship between the Clinical Characteristics in Patients with Neuromyelitis Optica Spectrum Disorders and Clinical Immune Indicators: A Retrospective Study

  2022cites this paper
• Anti‐monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder

  2022cites this paper
• The First Case Report of Preschool-Onset SS/SLE Coexisting With NMOSD of Chinese Origin

  2022cites this paper
• P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica

  2022cites this paper
• Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems

  2021cites this paper
• AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

  2021cites this paper
• Helicobacter pylori Infection and Extragastric Diseases—A Focus on the Central Nervous System

  2021cites this paper
• Diagnostic Imaging Approach to Pediatric Myelopathy

  2021cites this paper
• Optic Neuritis

  2021cites this paper
• Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis

  2021cites this paper
• Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder

  2021cites this paper
• Chronic Relapsing Inflammatory Optic Neuropathy (CRION)

  2021cites this paper
• Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

  2021cites this paper
• NDT_A_311942 1493..1503

  2021cites this paper
• Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

  2021cites this paper
• Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review

  2021cites this paper
• The Role of Exposomes in the Pathophysiology of Autoimmune Diseases I: Toxic Chemicals and Food

  2021cites this paper
• Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using optical coherence tomography angiography

  2021cites this paper
• High Prevalence of MMP9 −1562C/T Gene Polymorphism in an Iranian Population of Neuromyelitis Optica, A Pilot Study

  2021cites this paper
• Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies

  2021cites this paper
• Sporadic amyotrophic lateral sclerosis with seropositive neuromyelitis optica spectrum disorder

  2021cites this paper
• Neutrophil-to-Lymphocyte Ratio on Admission is an Independent Risk Factor for the Severity of Neurological Impairment at Disease Onset in Patients with a First Episode of Neuromyelitis Optica Spectrum Disorder

  2021cites this paper
• The Emerging Role of Microglia in Neuromyelitis Optica

  2021cites this paper
• Unraveling autoimmune and neurodegenerative diseases by amperometric serological detection of antibodies against aquaporin-4.

  2021cites this paper
• Intravenous immunoglobulin as the rescue treatment in NMOSD patients

  2021cites this paper
• Antiphospholipid antibodies and COVID-19

  2021cites this paper
• Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder

  2021cites this paper
• Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder

  2021cites this paper
• Functional impairment of CD19+CD24hiCD38hi B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy

  2021cites this paper
• Aquaporin-4-Antikörper-positive-Neuromyelitis-optica-Spektrum-Erkrankungen und Myelinoligodendrozytenglykoprotein-Antikörper-assoziierte Enzephalomyelitis. Eine Kurzübersicht

  2021cites this paper
• Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder

  2021cites this paper
• The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.

  2020cites this paper
• Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis

  2020cites this paper
• Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System

  2020cites this paper
• Immune System Under Fire: The Rise of Food Immune Reaction and Autoimmunity

  2020cites this paper
• Neuroimmunologic disorders in pregnancy.

  2020cites this paper
• Pathophysiological Basis Of Neuromyelitis Optica Spectrum Disorders: What Do We Know?

  2020cites this paper
• HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population

  2020cites this paper
• [Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis].

  2020cites this paper
• Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.

  2020cites this paper
• Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options

  2020cites this paper
• Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases

  2020cites this paper
• Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.

  2020cites this paper
• Reaction of food‐specific antibodies with different tissue antigens

  2020cites this paper
• Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations

  2020cites this paper
• Aquaporin regulation in metabolic organs.

  2020cites this paper
• Regulation of AQP4 in the Central Nervous System

  2020cites this paper
• Ocular manifestations in celiac disease: an overview

  2020cites this paper
• CNS lymphatics in health and disease

  2020cites this paper